A Case of Multiple Light Chain Multiple Myeloma Presenting with OVCF
Abstract
cells, which is often associated with the overproduction of monoclonal immunoglobulin or light chains. Osteolytic bone disease is a hallmark
of this condition. In this report, we present a case of delayed diagnosis of lambda light chain multiple myeloma, characterized by persistent
severe pain in the lower back and multiple fractures.
??Case Report: The patient visited eight hospitals due to persistent severe pain in the lower back for 17 months and was hospitalized nine
times. Multiple thoracolumbar vertebral compression fractures were identified through CT, MRI, and other relevant examinations conducted
five months after the onset of symptoms. A percutaneous vertebroplasty (PVP) was performed on five vertebrae. Following the procedure,
anti-osteoporosis medications, including denosumab, calcitonin, and teriparatide, were administered sequentially. Postoperatively, the patient's
pain was only temporarily alleviated, necessitating the daily use of oral analgesics. At the 17th month of the onset, bone marrow aspiration
and serum immunofixation electrophoresis were performed, leading to the final diagnosis of multiple myeloma, lambda light chain, DS stage
III, ISS stage III in group A. Following four cycles of chemotherapy, all indicators demonstrated complete remission (CR). By the sixth month
of chemotherapy, the patient's low back pain had significantly improved compared to before, allowing the patient to sit in a wheelchair.
??Conclusions: This case underscores the necessity for heightened vigilance regarding the potential for multiple myeloma in elderly patients who present with persistent severe pain and multiple lower back fractures, which may not solely be attributable to osteoporosis due to
age and bone mineral density loss. Specifically, when patients exhibit inadequate responses to anti-osteoporosis therapy, a thorough assessment should be conducted, integrating clinical symptoms, laboratory tests, and imaging findings. To establish a definitive diagnosis, additional
examinations, such as serum protein electrophoresis and bone marrow aspiration, are essential to rule out or confirm multiple myeloma, thereby preventing misdiagnosis or overlooked diagnoses.
Keywords
Full Text:
PDFReferences
[1] Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol, 2024;99(1):1-20.
[2] Cao JH, Zhang XH, Liu Y, et al. Serum free light chain normal ? light chain type multiple myeloma: a case report and literature review.
Leukemia Lymphoma, 2018;27(3):176-178.
[3] Coluzzi F, Rolke R, Mercadante S. Pain Management in Patients with Multiple Myeloma: An Update[J]. Cancers (Basel), 2019, 11(12).
[4] Diaz-delCastillo M, Andrews R E, Mandal A, et al. Bone Pain in Multiple Myeloma (BPMM)-A Protocol for a Prospective, Longitudinal, Observational Study[J]. Cancers (Basel), 2021, 13(7).
[5] Cheng J, Zhang W, Zhao Y, et al. Association of serum calcium levels with renal impairment and all-cause death in Chinese patients
with newly diagnosed multiple myeloma: a cross-sectional, longitudinal study[J]. Nutr Metab (Lond), 2021, 18(1):19.
[6] Milosavljevic J, Thomas A M. Teriparatide Associated Late Hypercalcemia: A Report of Two Cases and Literature Review[J]. J Community Hosp Intern Med Perspect, 2022, 12(1):54-58.
[7] Wang PF, Xu Y, Yan S, et al. The role of serum free light chain ?/? ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma patients. Chinese Journal of Hematology, 2016;37(5):377-382.
[8] Silva C, Costa A, Paiva D, et al. Light-Chain Multiple Myeloma: A Diagnostic Challenge[J]. Cureus, 2021, 13(10):e19131.
[9] Dutoit J C, Verstraete K L. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings[J]. Insights Imaging,
2016, 7(4):553-569.
[10] Hansford B G, Silbermann R. Advanced Imaging of Multiple Myeloma Bone Disease[J]. Front Endocrinol (Lausanne), 2018, 9:436.
[11] Dao A, McDonald M M, Savage P B, et al. Preventing osteolytic lesions and osteomyelitis in multiple myeloma[J]. J Bone Oncol, 2022,
37:100460.
[12] Terpos E, Raje N, Croucher P, et al. Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an
international phase 3 study[J]. Blood Adv, 2021, 5(3):725-736.
DOI: http://dx.doi.org/10.70711/mhr.v2i9.8482
Refbacks
- There are currently no refbacks.